Bradley W.Harrison (Brad)

Partner

(T) 1.216.586.7786

Brad Harrison is a trial attorney who represents clients in product liability and complex civil litigation in courts and before arbitration panels throughout the United States. He is no stranger to the courtroom, having served as trial counsel in several jury trials and as a member of numerous other trial teams throughout the country. Brad was a member of the team that achieved the record-breaking patent infringement verdict for Idenix Pharmaceuticals (subsidiary of Merck & Co.). After a two-week trial, the jury ordered Gilead Sciences to pay $2.54 billion for its infringement of an Idenix patent related to the treatment of patients with hepatitis C infection.

Brad devotes a large part of his practice to the defense of companies in product liability actions. He often defends companies in class actions and multidistrict litigation. Brad has successfully defended pharmaceutical and medical device manufacturers in cases involving prescription pharmaceuticals, stress urinary incontinence products, silicone gel breast implants, ultrasound-assisted and conventional liposuction equipment, and intraocular lenses. He also serves as counsel for R.J. Reynolds Tobacco Company in smoking and health litigation in Florida and throughout the country.

Brad also spends a considerable portion of his practice on commercial disputes, including complex business tort and contract litigation. These matters have included disputes regarding noncompetition agreements and business supply agreements as well as the representation of corporate policyholders in litigation against their insurers. In addition, Brad has been lead counsel for the defendant in a number of cases brought under the Fair Credit Reporting Act.

Experience

  • Merck obtains unanimous Supreme Court ruling in Fosamax® product liability caseJones Day represented Merck Sharp & Dohme Corp. in its unanimous win before the Supreme Court in a product liability case involving Merck's prescription medicine Fosamax®.
  • Idenix wins $2.54 billion jury verdict in Gilead patent dispute involving hepatitis C drugsAfter a nine day trial and less than two hours of jury deliberation, Jones Day, on behalf of Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co.), won the largest patent infringement verdict in U.S. history to date, involving a multi-billion dollar patent dispute with Gilead Sciences Inc. over sofosbuvir, the active ingredient in Gilead’s hepatitis C drugs Sovaldi® and Harvoni®.
  • R.J. Reynolds wins jury verdict in Coursey "Engle progeny" trialOn August 25, 2016, following nine days of trial, a jury in Deland, Florida returned a verdict in favor of Jones Day client R.J. Reynolds Tobacco Company in a personal injury action.
  • R.J. Reynolds wins jury verdict in Dupre "Engle progeny" trialJones Day client R.J. Reynolds Tobacco Company obtained a complete defense verdict in an "Engle progeny" case in which the plaintiff alleged her husband, Richard Dupre, had died at age 45 due to being addicted to R.J. Reynolds' cigarettes.
  • R.J. Reynolds wins jury verdict in Rounds "Engle progeny" trialOn January 26, 2016, following eleven days of trial, a jury in Daytona Beach, Florida returned a verdict in favor of Jones Day client R.J. Reynolds Tobacco Company in a personal injury action.
  • R.J. Reynolds wins jury verdict in Gordon ''Engle progeny'' trialOn October 5, 2015, a jury in Punta Gorda, Florida returned a verdict favorable to Jones Day client R.J. Reynolds Tobacco Company following 10 days of trial and approximately 4 hours of deliberation in an "Engle progeny" lawsuit.
  • R.J. Reynolds wins jury verdict in Hecht ''Engle progeny'' lawsuitOn February 10, 2015, following six days of trial, a jury in Jacksonville, Florida returned a verdict in favor of Jones Day client R.J. Reynolds Tobacco Company in a personal injury action.
  • American Greetings resolves putative class action over life insurance policiesJones Day client American Greetings Corporation resolved a putative class action complaint brought by plaintiffs alleging that American Greetings misused employee information by purchasing life insurance policies on its employees, and then wrongfully collecting policy benefits.
  • R.J. Reynolds wins jury verdict in latest federal "Engle progeny" lawsuitJones Day successfully represented R.J. Reynolds Tobacco Company in the latest "Engle progeny" lawsuit tried to verdict in Florida federal court.
  • R.J. Reynolds wins jury verdict in Campbell ''Engle progeny'' lawsuitJones Day secures complete defense verdict for R.J. Reynolds Tobacco Company in an "Engle progeny" lawsuit.
  • Mentor wins complete defense verdict after trial in case alleging injuries caused by ObTapeThe Plaintiff in this case asserted negligence and failure to warn claims against Jones Day client Mentor Corporation, alleging that she had suffered injuries due to ObTape, a surgically-implanted mesh sling used for treatment of stress urinary incontinence.
  • Mentor wins dismissal of class action seeking medical monitoringOn August 5, 2008, the U.S. District Court for the Western District of Missouri granted Jones Day client, Mentor Corporation's, motion to dismiss.
  • Bradley Company prevails in breach of contract counterclaim in copyright and trademark infringement case involving health club management softwareThe court granted a motion for judgment on the pleadings on a breach of contract counterclaim by Jones Day client The Bradley Company, Ltd. in a copyright and trademark infringement case involving health club management software.
  • Additional Publications

    • November 2017Initial Coin Offerings—A Singapore Perspective
    • September 2017Blockchain for Business
    • May 2016Supreme Court Relies on Attorney Notes in Considering a Claim of Racial Profiling in Juror Selection
    • 2010The Meaning of the Parallel Requirements Exception Under Lohr and Riegel, 65(3) N.Y.U. Ann. Surv. Am. L. 545
    • 2009Making Class Actions Work: The Untapped Potential of the Internet, University of Pittsburgh Law Review
    • Summer 2007Direct-to-Consumer Advertising and the Learned Intermediary Doctrine: Trends and Safe Harbors for Pharmaceutical Manufacturers, Practice Perspectives: Product Liability & Tort Litigation
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.